BioWorld

March 25, 2008

Zogenix Eyes Public Markets, Files for Potential $86M IPO

Only days after the FDA accepted for review Zogenix Inc.'s new drug application for its needle-free sumatriptan candidate, the San Diego-based firm filed for an initial public offering. (BioWorld Today) Read More

Cytokinetics Sees Shares Rise on Positive Heart Drug Data

Parkinson's Treated with SCNT as Genomics Data Find Home

NewCo News: Influmedix Plans to Go Multiple Rounds With M Channel Target

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Science

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Asia

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...